A systematic review of prion therapeutics in experimental models.

Prion diseases are transmissible, invariably fatal, neurodegenerative diseases which include Creutzfeldt-Jakob disease (CJD) in humans and bovine spongiform encephalopathy and scrapie in animals. A large number of putative treatments have been studied in experimental models over the past 30 years, with at best modest disease-modifying effects. The arrival of variant CJD in the UK in the 1990s has intensified the search for effective therapeutic agents, using an increasing number of animal, cellular and in vitro models with some recent promising proof of principle studies. Here, for the first time, we present a comprehensive systematic, rather than selective, review of published data on experimental approaches to prion therapeutics to provide a scientific resource for informing future therapeutics research, both in laboratory models and in clinical studies.

[1]  J. Griffith,et al.  Nature of the Scrapie Agent: Self-replication and Scrapie , 1967, Nature.

[2]  J. Griffith,et al.  Self-replication and scrapie. , 1967, Nature.

[3]  I. Gresser,et al.  An attempt to modify scrapie in mice by the administration of interferon. , 1968, The Journal of general virology.

[4]  D. Haig,et al.  The effect of beta-propiolactone on the scrapie agent. , 1968, The Journal of general virology.

[5]  E. J. Field,et al.  Failure of interferon to modify scrapie in the mouse. , 1969, The Journal of general virology.

[6]  H. Fraser,et al.  Pathogenesis of Scrapie in the Mouse: the Role of the Spleen , 1970, Nature.

[7]  M. Raff,et al.  Scrapie in Immunologically Deficient Mice , 1971, Nature.

[8]  M. Worthington,et al.  Lack of effect of immunosuppression on scrapie infection in mice. , 1971, The Journal of general virology.

[9]  K. W. Cochran Failure of adenine arabinoside to modify scrapie in mice. , 1971, The Journal of general virology.

[10]  H. Fraser,et al.  Scrapie: Effect of Dh gene on incubation period of extraneurally injected agent , 1972, Heredity.

[11]  M. Worthington Interferon System in Mice Infected with the Scrapie Agent , 1972, Infection and immunity.

[12]  H. Fraser,et al.  Developmental Maturation of Susceptibility to Scrapie in Mice , 1973, Nature.

[13]  D. Porter,et al.  Failure to demonstrate a humoral immune response to scrapie infection in mice. , 1973, Journal of immunology.

[14]  H. Fraser,et al.  Reduced susceptibility to scrapie in mice after steroid administration , 1974, Nature.

[15]  H. Fraser,et al.  SLOW ENCEPHALOPATHIES, INFLAMMATORY RESPONSES, AND ARACHIS OIL , 1975, The Lancet.

[16]  L. B. Allen,et al.  ACCELERATION OF SCRAPIE IN MICE BY TARGET‐ORGAN TREATMENT WITH INTERFERON INDUCERS , 1977, Annals of the New York Academy of Sciences.

[17]  M. Ravid,et al.  EFFECT OF A SINGLE DOSE OF DIMETHYL SULPHOXIDE ON RENAL AMYLOIDOSIS , 1977, The Lancet.

[18]  H. Fraser,et al.  Studies of the lymphoreticular system in the pathogenesis of scrapie: the role of spleen and thymus. , 1978, Journal of comparative pathology.

[19]  P. Burge COLOPHONY AND ASTHMA , 1979, The Lancet.

[20]  R. Kimberlin,et al.  ANTIVIRAL COMPOUND EFFECTIVE AGAINST EXPERIMENTAL SCRAPIE , 1979, The Lancet.

[21]  J. Tateishi,et al.  Antibiotics and antivirals do not modify experimentally-induced Creutzfeldt-Jakob disease in mice , 1981, Journal of neurology, neurosurgery, and psychiatry.

[22]  A. Woody,et al.  Spectroscopic studies of Congo Red binding to RNA polymerase. , 1981, Biochimica et biophysica acta.

[23]  M. Ravid,et al.  Prolonged dimethylsulphoxide treatment in 13 patients with systemic amyloidosis. , 1982, Annals of the rheumatic diseases.

[24]  S. Prusiner,et al.  Identification of a protein that purifies with the scrapie prion. , 1982, Science.

[25]  S. Prusiner Novel proteinaceous infectious particles cause scrapie. , 1982, Science.

[26]  R. L. Chandler,et al.  Failure to modify scrapie in mice by administration of interferon or anti-interferon globulin. , 1983, The Journal of general virology.

[27]  S. Prusiner,et al.  Antibodies to a scrapie prion protein , 1984, Nature.

[28]  H. Diringer,et al.  The reticuloendothelial system in scrapie pathogenesis. , 1984, The Journal of general virology.

[29]  V. M. Roikhel',et al.  Influence of aminasine on experimental scrapie in mice. , 1984, Acta virologica.

[30]  Roĭkhel' Vm,et al.  Influence of aminasine on experimental scrapie in mice. , 1984 .

[31]  R. Kimberlin,et al.  Suppression of scrapie infection in mice by heteropolyanion 23, dextran sulfate, and some other polyanions , 1986, Antimicrobial Agents and Chemotherapy.

[32]  A. Dickinson,et al.  Prolongation of scrapie incubation period by an injection of dextran sulphate 500 within the month before or after infection. , 1986, The Journal of general virology.

[33]  H. Wiśniewski,et al.  Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins , 1987, Journal of virology.

[34]  C. Masullo,et al.  Amphotericin B delays the incubation period of scrapie in intracerebrally inoculated hamsters. , 1987, The Journal of general virology.

[35]  S. Prusiner,et al.  Immunoaffinity purification and neutralization of scrapie prion infectivity. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[36]  P. Casaccia,et al.  Amphotericin B: a novel class of antiscrapie drugs. , 1989, The Journal of infectious diseases.

[37]  S. Prusiner,et al.  Spontaneous neurodegeneration in transgenic mice with mutant prion protein , 1990, Science.

[38]  S. Prusiner,et al.  Scrapie and cellular prion proteins differ in their kinetics of synthesis and topology in cultured cells , 1990, The Journal of cell biology.

[39]  G. J. Raymond,et al.  The scrapie-associated form of PrP is made from a cell surface precursor that is both protease- and phospholipase-sensitive. , 1991, The Journal of biological chemistry.

[40]  B. Ehlers,et al.  Chemoprophylaxis of scrapie in mice. , 1991, The Journal of general virology.

[41]  M. Pocchiari,et al.  Amphotericin B treatment dissociates in vivo replication of the scrapie agent from PrP accumulation , 1992, Nature.

[42]  B. Fitzgerald,et al.  Squalestatin 1, a potent inhibitor of squalene synthase, which lowers serum cholesterol in vivo. , 1992, The Journal of biological chemistry.

[43]  B. Caughey,et al.  Potent Inhibition of Scrapie‐Associated PrP Accumulation by Congo Red , 1992, Journal of neurochemistry.

[44]  H. Fraser,et al.  The basis of strain variation in scrapie. , 1992 .

[45]  M. Salvatore,et al.  Sulphate polyanions prolong the incubation period of scrapie-infected hamsters. , 1992, The Journal of general virology.

[46]  B. Caughey,et al.  Congo red inhibition of scrapie agent replication , 1993, Journal of virology.

[47]  S. Prusiner,et al.  Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[48]  A. Aguzzi,et al.  Mice devoid of PrP are resistant to scrapie , 1993, Cell.

[49]  G. J. Raymond,et al.  Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells , 1993, Journal of virology.

[50]  S. Ben‐Sasson,et al.  Heparin‐like molecules bind differentially to prion‐proteins and change their intracellular metabolic fate , 1993, Journal of cellular physiology.

[51]  H. Ushijima,et al.  Cytoprotective effect of NMDA receptor antagonists on prion protein (PrionSc)-induced toxicity in rat cortical cell cultures. , 1993, European journal of pharmacology.

[52]  G. J. Raymond,et al.  Binding of the protease-sensitive form of PrP (prion protein) to sulfated glycosaminoglycan and congo red [corrected] , 1994, Journal of virology.

[53]  G. Forloni,et al.  Conformational polymorphism of the amyloidogenic and neurotoxic peptide homologous to residues 106-126 of the prion protein. , 1994, The Journal of biological chemistry.

[54]  Binding of the Protease-Sensitive Form of PrP (Prion Protein) to Sulfated Glycosaminoglycan and Congo Red , 1994 .

[55]  A. Aguzzi,et al.  No propagation of prions in mice devoid of PrP , 1994, Cell.

[56]  B. Caughey,et al.  Inhibition of scrapie-associated PrP accumulation. Probing the role of glycosaminoglycans in amyloidogenesis. , 1994, Molecular neurobiology.

[57]  W. Ee Women of courage: commercial sex workers mobilize for HIV / AIDS prevention in Nigeria. , 1994 .

[58]  D. Dormont,et al.  Pharmacological studies of a new derivative of amphotericin B, MS-8209, in mouse and hamster scrapie. , 1994, The Journal of general virology.

[59]  A. Aguzzi,et al.  High Prion and PrPSc Levels but Delayed Onset of Disease in Scrapie-Inoculated Mice Heterozygous for a Disrupted PrP Gene , 1994, Molecular medicine.

[60]  J. Aiken,et al.  Amphotericin B delays both scrapie agent replication and PrP-res accumulation early in infection , 1994, Journal of virology.

[61]  R. Marsh,et al.  Distinct PrP properties suggest the molecular basis of strain variation in transmissible mink encephalopathy , 1994, Journal of virology.

[62]  J. Pettegrew,et al.  Development of small molecule probes for the Beta-amyloid protein of Alzheimer's Disease , 1994, Neurobiology of Aging.

[63]  D. Dormont,et al.  MS-8209, a new amphotericin B derivative, provides enhanced efficacy in delaying hamster scrapie , 1995, Antimicrobial agents and chemotherapy.

[64]  P. Lantos,et al.  Transmission of fatal familial insomnia to laboratory animals , 1995, The Lancet.

[65]  K. Moulder,et al.  Sulfated Glycans Stimulate Endocytosis of the Cellular Isoform of the Prion Protein, PrPC, in Cultured Cells (*) , 1995, The Journal of Biological Chemistry.

[66]  L. Gianni,et al.  New drug therapy of amyloidoses: resorption of AL-type deposits with 4'-iodo-4'-deoxydoxorubicin. , 1995, Blood.

[67]  E. Arbustini,et al.  Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[68]  M. Pocchiari,et al.  Congo red prolongs the incubation period in scrapie-infected hamsters , 1995, Journal of virology.

[69]  F. Cohen,et al.  Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein , 1995, Cell.

[70]  J. Neurodegenerative Diseases , 1996, GWUMC Department of Biochemistry and Molecular Biology Annual Spring Symposia.

[71]  Andrew F. Hill,et al.  Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD , 1996, Nature.

[72]  A. Hofman,et al.  A new variant of Creutzfeldt-Jakob disease in the UK , 1996, The Lancet.

[73]  D. Dormont,et al.  Differential effects of a new amphotericin B derivative, MS-8209, on mouse BSE and scrapie: implications for the mechanism of action of polyene antibiotics. , 1996, Research in virology.

[74]  S. Prusiner,et al.  Chemical chaperones interfere with the formation of scrapie prion protein. , 1996, The EMBO journal.

[75]  M. Groschup,et al.  Generation of Monoclonal Antibodies against Human Prion Proteins in PrP0/0 Mice , 1996, Molecular medicine.

[76]  S. Prusiner,et al.  Evidence for the Conformation of the Pathologic Isoform of the Prion Protein Enciphering and Propagating Prion Diversity , 1996, Science.

[77]  M. Smits,et al.  PrP genotype contributes to determining survival times of sheep with natural scrapie. , 1996, The Journal of general virology.

[78]  D R Burton,et al.  Circumventing tolerance to generate autologous monoclonal antibodies to the prion protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[79]  J. Rossier,et al.  Transmission of the BSE Agent to Mice in the Absence of Detectable Abnormal Prion Protein , 1997, Science.

[80]  S. Cousens,et al.  Transmissions to mice indicate that ‘new variant’ CJD is caused by the BSE agent , 1997, Nature.

[81]  F. Cohen,et al.  COOH-terminal sequence of the cellular prion protein directs subcellular trafficking and controls conversion into the scrapie isoform. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[82]  A. Aguzzi,et al.  A crucial role for B cells in neuroinvasive scrapie , 1997, Nature.

[83]  R. Riek,et al.  Prion (PrPSc)-specific epitope defined by a monoclonal antibody , 1997, Nature.

[84]  F. Cohen,et al.  Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[85]  D. Dormont,et al.  Late treatment with polyene antibiotics can prolong the survival time of scrapie-infected animals , 1997, Journal of virology.

[86]  Andrew F. Hill,et al.  The same prion strain causes vCJD and BSE , 1997, Nature.

[87]  G. Forloni,et al.  Effectiveness of anthracycline against experimental prion disease in Syrian hamsters. , 1997, Science.

[88]  R. Shin,et al.  Protective prion protein polymorphisms against sporadic Creutzfeldt-Jakob disease , 1998, The Lancet.

[89]  D. Kirsch,et al.  Prion Rods Contain Small Amounts of Two Host Sphingolipids as Revealed by Thin-Layer Chromatography and Mass Spectrometry , 1998, Biological chemistry.

[90]  J. Pettegrew,et al.  Chrysamine-G, a lipophilic analogue of Congo red, inhibits A beta-induced toxicity in PC12 cells. , 1998, Life sciences.

[91]  K. Heeg,et al.  Bacterial DNA as immune cell activator. , 1998, Trends in microbiology.

[92]  B. Chesebro,et al.  Specific Inhibition of in Vitro Formation of Protease-resistant Prion Protein by Synthetic Peptides* , 1998, The Journal of Biological Chemistry.

[93]  B. Caughey,et al.  Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[94]  B. Chesebro,et al.  Structural Aspects of Congo Red as an Inhibitor of Protease‐Resistant Prion Protein Formation , 1998, Journal of neurochemistry.

[95]  Dapsone to delay symptoms in Creutzfeldt-Jakob disease , 1998, The Lancet.

[96]  Claudio Soto,et al.  β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy , 1998, Nature Medicine.

[97]  R. Gabizon,et al.  The Anti-prion Activity of Congo Red , 1998, The Journal of Biological Chemistry.

[98]  A. Aguzzi,et al.  PrP expression in B lymphocytes is not required for prion neuroinvasion , 1998, Nature Medicine.

[99]  P. Eikelenboom,et al.  Heparan Sulfate Proteoglycan Is Associated with Amyloid Plaques and Neuroanatomically Targeted PrP Pathology throughout the Incubation Period of Scrapie-Infected Mice , 1998, Experimental Neurology.

[100]  H. Fraser,et al.  Scrapie replication in lymphoid tissues depends on prion protein-expressing follicular dendritic cells , 1999, Nature Medicine.

[101]  A. Dickinson,et al.  Prophylactic potential of pentosan polysulphate in transmissible spongiform encephalopathies , 1999, The Lancet.

[102]  D. Dormont,et al.  New insight into abnormal prion protein using monoclonal antibodies. , 1999, Biochemical and biophysical research communications.

[103]  D. Barritault,et al.  A substituted dextran enhances muscle fiber survival and regeneration in ischemic and denervated rat EDL muscle , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[104]  K. Adjou,et al.  Inhibiting scrapie neuroinvasion by polyene antibiotic treatment of SCID mice. , 1999, The Journal of general virology.

[105]  J Collinge,et al.  Reversible conversion of monomeric human prion protein between native and fibrilogenic conformations. , 1999, Science.

[106]  Z. Meiner,et al.  Protease-resistant and Detergent-insoluble Prion Protein Is Not Necessarily Associated with Prion Infectivity* , 1999, The Journal of Biological Chemistry.

[107]  B. Chesebro,et al.  Species-Independent Inhibition of Abnormal Prion Protein (PrP) Formation by a Peptide Containing a Conserved PrP Sequence , 1999, Journal of Virology.

[108]  B. Caughey,et al.  Specific binding of normal prion protein to the scrapie form via a localized domain initiates its conversion to the protease‐resistant state , 1999, The EMBO journal.

[109]  B. Chesebro,et al.  Effectiveness of Polyene Antibiotics in Treatment of Transmissible Spongiform Encephalopathy in Transgenic Mice Expressing Syrian Hamster PrP Only in Neurons , 1999, Journal of Virology.

[110]  MS-8209, a water-soluble amphotericin B derivative, affects both scrapie agent replication and PrPres accumulation in Syrian hamster scrapie. , 1999, The Journal of general virology.

[111]  F. Cohen,et al.  Elimination of prions by branched polyamines and implications for therapeutics. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[112]  B. Caughey,et al.  Lysosomotropic Agents and Cysteine Protease Inhibitors Inhibit Scrapie-Associated Prion Protein Accumulation , 2000, Journal of virology.

[113]  A. Mangé,et al.  Effect of Congo Red on Wild‐Type and Mutated Prion Proteins in Cultured Cells , 2000, Journal of neurochemistry.

[114]  T. Wisniewski,et al.  Reversion of prion protein conformational changes by synthetic b-sheet breaker peptides , 2000, The Lancet.

[115]  M. Pasparakis,et al.  Tumor Necrosis Factor Alpha-Deficient, but Not Interleukin-6-Deficient, Mice Resist Peripheral Infection with Scrapie , 2000, Journal of Virology.

[116]  P. Lantos,et al.  Species-barrier-independent prion replication in apparently resistant species. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[117]  K. Winklhofer,et al.  Cationic Lipopolyamines Induce Degradation of PrPSc in Scrapie-Infected Mouse Neuroblastoma Cells , 2000, Biological chemistry.

[118]  D. Dormont,et al.  Pharmacological manipulation of early PrPres accumulation in the spleen of scrapie-infected mice. , 2000, Archives of virology. Supplementum.

[119]  J. Hauw,et al.  MS-8209, an amphotericin B analogue, delays the appearance of spongiosis, astrogliosis and PrPres accumulation in the brain of scrapie-infected hamsters. , 2000, Journal of comparative pathology.

[120]  W. Caughey,et al.  Porphyrin and phthalocyanine antiscrapie compounds. , 2000, Science.

[121]  A. Aguzzi,et al.  Impaired prion replication in spleens of mice lacking functional follicular dendritic cells. , 2000, Science.

[122]  D. Dormont,et al.  Opposite Effects of Dextran Sulfate 500, the Polyene Antibiotic MS-8209, and Congo Red on Accumulation of the Protease-Resistant Isoform of PrP in the Spleens of Mice Inoculated Intraperitoneally with the Scrapie Agent , 2000, Journal of Virology.

[123]  F. Cohen,et al.  Mimicking dominant negative inhibition of prion replication through structure-based drug design. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[124]  G. Forloni,et al.  Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro. , 2000, Journal of molecular biology.

[125]  I. Gilbert,et al.  Screening Congo Red and its analogues for their ability to prevent the formation of PrP-res in scrapie-infected cells. , 2000, The Journal of general virology.

[126]  F. Mackay,et al.  Temporary inactivation of follicular dendritic cells delays neuroinvasion of scrapie , 2000, Nature Medicine.

[127]  B. Chesebro,et al.  Inhibition of formation of protease-resistant prion protein by Trypan Blue, Sirius Red and other Congo Red analogs. , 2000, Archives of virology. Supplementum.

[128]  A. Mangé,et al.  Amphotericin B Inhibits the Generation of the Scrapie Isoform of the Prion Protein in Infected Cultures , 2000, Journal of Virology.

[129]  M. Walport,et al.  Temporary depletion of complement component C3 or genetic deficiency of C1q significantly delays onset of scrapie , 2001, Nature Medicine.

[130]  D. Dormont,et al.  The 37‐kDa/67‐kDa laminin receptor acts as the cell‐surface receptor for the cellular prion protein , 2001, The EMBO journal.

[131]  I. Xenarios,et al.  Complement facilitates early prion pathogenesis , 2001, Nature Medicine.

[132]  C. Culmsee,et al.  A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid β‐peptide , 2001 .

[133]  D. Riesner,et al.  Intracellular re‐routing of prion protein prevents propagation of PrPSc and delays onset of prion disease , 2001, The EMBO journal.

[134]  C. Bostock,et al.  Scrapie strains maintain biological phenotypes on propagation in a cell line in culture , 2001, The EMBO journal.

[135]  G. M. Cole,et al.  Phenolic anti-inflammatory antioxidant reversal of Aβ-induced cognitive deficits and neuropathology , 2001, Neurobiology of Aging.

[136]  J. Collinge Prion diseases of humans and animals: their causes and molecular basis. , 2001, Annual review of neuroscience.

[137]  F. Heppner,et al.  Prevention of Scrapie Pathogenesis by Transgenic Expression of Anti-Prion Protein Antibodies , 2001, Science.

[138]  F E Cohen,et al.  Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[139]  J. Samarut,et al.  Efficient Transmission of Two Different Sheep Scrapie Isolates in Transgenic Mice Expressing the Ovine PrP Gene , 2001, Journal of Virology.

[140]  S. Prusiner,et al.  Shattuck lecture--neurodegenerative diseases and prions. , 2001, The New England journal of medicine.

[141]  Y. Cordeiro,et al.  DNA Converts Cellular Prion Protein into the β-Sheet Conformation and Inhibits Prion Peptide Aggregation* , 2001, The Journal of Biological Chemistry.

[142]  G. Cole,et al.  The Curry Spice Curcumin Reduces Oxidative Damage and Amyloid Pathology in an Alzheimer Transgenic Mouse , 2001, The Journal of Neuroscience.

[143]  V. Perry,et al.  Early behavioural changes in scrapie‐affected mice and the influence of dapsone , 2001, The European journal of neuroscience.

[144]  D. Dormont,et al.  Identification of interaction domains of the prion protein with its 37‐kDa/67‐kDa laminin receptor , 2001, The EMBO journal.

[145]  M. Enari,et al.  Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[146]  M. Beal,et al.  Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders , 2001, Annals of neurology.

[147]  F. Cohen,et al.  Branched Polyamines Cure Prion-Infected Neuroblastoma Cells , 2001, Journal of Virology.

[148]  J. Collinge,et al.  Location and properties of metal-binding sites on the human prion protein , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[149]  I. Cohen,et al.  Modulation of proteinase‐K resistant prion protein by prion peptide immunization , 2001, European journal of immunology.

[150]  Pauline M. Rudd,et al.  Antibodies inhibit prion propagation and clear cell cultures of prion infectivity , 2001, Nature.

[151]  B. Chesebro,et al.  Sulfated glycans and elevated temperature stimulate PrPSc‐dependent cell‐free formation of protease‐resistant prion protein , 2001, The EMBO journal.

[152]  F. Cohen,et al.  Dominant-negative inhibition of prion replication in transgenic mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[153]  S. Ratté,et al.  Post‐natal knockout of prion protein alters hippocampal CA1 properties, but does not result in neurodegeneration , 2002, The EMBO journal.

[154]  J. Grassi,et al.  Filipin Prevents Pathological Prion Protein Accumulation by Reducing Endocytosis and Inducing Cellular PrP Release* , 2002, The Journal of Biological Chemistry.

[155]  E. Sigurdsson,et al.  Immunization delays the onset of prion disease in mice. , 2002, The American journal of pathology.

[156]  H. Kretzschmar,et al.  Postexposure prophylaxis against prion disease with a stimulator of innate immunity , 2002, The Lancet.

[157]  C. Masters,et al.  Quinacrine does not prolong survival in a murine Creutzfeldt‐Jakob disease model , 2002, Annals of neurology.

[158]  Alun Williams,et al.  Cyclo-oxygenase inhibitors protect against prion-induced neurotoxicity in vitro , 2002, Neuroreport.

[159]  J. Ávila,et al.  Glycosaminoglycans and β-amyloid, prion and tau peptides in neurodegenerative diseases , 2002, Peptides.

[160]  M. Famulok,et al.  Prion‐Protein‐Specific Aptamer Reduces PrPSc Formation , 2002, Chembiochem : a European journal of chemical biology.

[161]  N. Mabbott,et al.  Temporary Blockade of the Tumor Necrosis Factor Receptor Signaling Pathway Impedes the Spread of Scrapie to the Brain , 2002, Journal of Virology.

[162]  G. Forloni,et al.  Tetracyclines affect prion infectivity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[163]  S. Prusiner,et al.  Cholesterol Depletion and Modification of COOH-Terminal Targeting Sequence of the Priori Protein Inhibit Formation of the Scrapie Isoform , 2002 .

[164]  A. Aguzzi,et al.  Soluble Dimeric Prion Protein Binds PrPSc In Vivo and Antagonizes Prion Disease , 2003, Cell.

[165]  E. Sigurdsson,et al.  Copper Chelation Delays the Onset of Prion Disease* , 2003, Journal of Biological Chemistry.

[166]  Sebastian Brandner,et al.  Depleting Neuronal PrP in Prion Infection Prevents Disease and Reverses Spongiosis , 2003, Science.

[167]  J. Collinge,et al.  Regional heterogeneity of cellular prion protein isoforms in the mouse brain. , 2003, Brain : a journal of neurology.

[168]  L. Meijer,et al.  Isolation of drugs active against mammalian prions using a yeast-based screening assay , 2003, Nature Biotechnology.

[169]  F. Cohen,et al.  Potent inhibition of scrapie prion replication in cultured cells by bis-acridines , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[170]  R. Gabizon,et al.  Dimethyl sulfoxide delays PrPsc accumulation and disease symptoms in prion-infected hamsters , 2003, Brain Research.

[171]  W. Caughey,et al.  Prophylactic and therapeutic effects of phthalocyanine tetrasulfonate in scrapie-infected mice. , 2003, The Journal of infectious diseases.

[172]  Tomoya Kinumi,et al.  Effects of beta-sheet breaker peptide polymers on scrapie-infected mouse neuroblastoma cells and their affinities to prion protein fragment PrP(81-145). , 2003, Organic & biomolecular chemistry.

[173]  I. Mcconnell,et al.  Follicular Dendritic Cell Dedifferentiation by Treatment with an Inhibitor of the Lymphotoxin Pathway Dramatically Reduces Scrapie Susceptibility , 2003, Journal of Virology.

[174]  E. Sigurdsson,et al.  Anti-prion antibodies for prophylaxis following prion exposure in mice , 2003, Neuroscience Letters.

[175]  D. Harris Trafficking, turnover and membrane topology of PrP. , 2003, British medical bulletin.

[176]  P. Henklein,et al.  Immunisation with a synthetic prion protein-derived peptide prolongs survival times of mice orally exposed to the scrapie agent , 2003, Neuroscience Letters.

[177]  C. Leucht,et al.  The 37 kDa/67 kDa laminin receptor is required for PrPSc propagation in scrapie‐infected neuronal cells , 2003, EMBO reports.

[178]  M. Salmona,et al.  In vitro Evaluation of the Anti-prionic Activity of Newly Synthesized Congo Red Derivatives , 2003, Arzneimittelforschung.

[179]  R. Gabizon,et al.  Novel heparan mimetics potently inhibit the scrapie prion protein and its endocytosis. , 2003, Biochemical and biophysical research communications.

[180]  J. Collinge,et al.  Monoclonal antibodies inhibit prion replication and delay the development of prion disease , 2003, Nature.

[181]  S. Mohri,et al.  Generation of antibodies against prion protein by scrapie-infected cell immunization of PrP(0/0) mice. , 2003, Hybridoma and hybridomics.

[182]  F. Heppner,et al.  Immune system and peripheral nerves in propagation of prions to CNS. , 2003, British medical bulletin.

[183]  J. Hope,et al.  Characterization of 2′-Fluoro-RNA Aptamers That Bind Preferentially to Disease-associated Conformations of Prion Protein and Inhibit Conversion* , 2003, Journal of Biological Chemistry.

[184]  T. Ben-Hur,et al.  Copper binding to PrPC may inhibit prion disease propagation , 2003, Brain Research.

[185]  G. Forloni,et al.  Evaluation of Quinacrine Treatment for Prion Diseases , 2003, Journal of Virology.

[186]  S. Supattapone,et al.  In vitro amplification of protease-resistant prion protein requires free sulfhydryl groups. , 2003, Biochemistry.

[187]  J. Chabry,et al.  Specific inhibition of pathological prion protein accumulation by small interfering RNAs , 2003, Journal of Cell Science.

[188]  D. Dormont,et al.  A novel generation of heparan sulfate mimetics for the treatment of prion diseases. , 2003, The Journal of general virology.

[189]  I. Gilbert,et al.  In vitro cell-free conversion of bacterial recombinant PrP to PrPres as a model for conversion. , 2003, The Journal of general virology.

[190]  E. Wolf,et al.  Polyclonal Anti-PrP Auto-antibodies Induced with Dimeric PrP Interfere Efficiently with PrPSc Propagation in Prion-infected Cells* , 2003, The Journal of Biological Chemistry.

[191]  G. J. Raymond,et al.  Inhibition of Protease-Resistant Prion Protein Accumulation In Vitro by Curcumin , 2003, Journal of Virology.

[192]  S. Prusiner,et al.  Differential Inhibition of Prion Propagation by Enantiomers of Quinacrine , 2003, Laboratory Investigation.

[193]  J. Chapuis,et al.  Efficient and specific down-regulation of prion protein expression by RNAi. , 2003, Biochemical and biophysical research communications.

[194]  I. Cohen,et al.  Complete Freund's adjuvant immunization prolongs survival in experimental prion disease in mice , 2003, Journal of neuroscience research.

[195]  B. Caughey,et al.  New Inhibitors of Scrapie-Associated Prion Protein Formation in a Library of 2,000 Drugs and Natural Products , 2003, Journal of Virology.

[196]  S. Akira,et al.  Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration , 2004, Nature Medicine.

[197]  J. Solassol,et al.  Anti‐PrP antibodies block PrPSc replication in prion‐infected cell cultures by accelerating PrPC degradation , 2004, Journal of neurochemistry.

[198]  S. Prusiner,et al.  Sulfated glycosaminoglycans in amyloid plaques of prion diseases , 2004, Acta Neuropathologica.

[199]  J. Solassol,et al.  Cationic phosphorus-containing dendrimers reduce prion replication both in cell culture and in mice infected with scrapie. , 2004, The Journal of general virology.

[200]  N. Ishiguro,et al.  Cell-surface retention of PrPC by anti-PrP antibody prevents protease-resistant PrP formation. , 2004, The Journal of general virology.

[201]  J. Ironside,et al.  Variant Creutzfeldt-Jakob disease. , 2004, Folia neuropathologica.

[202]  N. Ishiguro,et al.  Antigenic characterization of an abnormal isoform of prion protein using a new diverse panel of monoclonal antibodies. , 2004, Virology.

[203]  P. Mantegazza,et al.  Evaluation of Anti-Prion Activity of Congo Red and its Derivatives in Experimentally Infected Hamsters , 2004, Arzneimittelforschung.

[204]  M. Head,et al.  Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient , 2004, The Lancet.

[205]  B. Caughey,et al.  Evaluation of new cell culture inhibitors of protease-resistant prion protein against scrapie infection in mice. , 2004, The Journal of general virology.

[206]  Alun Williams,et al.  Phospholipase A2 Inhibitors or Platelet-activating Factor Antagonists Prevent Prion Replication* , 2004, Journal of Biological Chemistry.

[207]  Jun-ichi Kira,et al.  Quinoline Derivatives Are Therapeutic Candidates for Transmissible Spongiform Encephalopathies , 2004, Journal of Virology.

[208]  Y. Kuroiwa,et al.  Non-glycosylphosphatidylinositol (GPI)-anchored recombinant prion protein with dominant-negative mutation inhibits PrPSc replication in vitro , 2004, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[209]  M. Salmona,et al.  Squalestatin Cures Prion-infected Neurons and Protects Against Prion Neurotoxicity* , 2004, Journal of Biological Chemistry.

[210]  J. Collinge,et al.  PrPSc Binding Antibodies Are Potent Inhibitors of Prion Replication in Cell Lines* , 2004, Journal of Biological Chemistry.

[211]  G. Millhauser Copper binding in the prion protein. , 2004, Accounts of chemical research.

[212]  Mark Head,et al.  Preclinical variant CJD after blood transfusion in a PRNP codon 129 heterozygous patient , 2004 .

[213]  J Mackenzie,et al.  Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion , 2004, The Lancet.

[214]  I. Gilbert,et al.  Synthesis of analogues of Congo red and evaluation of their anti-prion activity. , 2004, Journal of medicinal chemistry.

[215]  T. Iwaki,et al.  Treatment of Transmissible Spongiform Encephalopathy by Intraventricular Drug Infusion in Animal Models , 2004, Journal of Virology.

[216]  Seong-Wook Yun,et al.  The Tyrosine Kinase Inhibitor STI571 Induces Cellular Clearance of PrPSc in Prion-infected Cells* , 2004, Journal of Biological Chemistry.

[217]  S. Lehmann,et al.  Inhibition of PrPSc formation by lentiviral gene transfer of PrP containing dominant negative mutations , 2004, Journal of Cell Science.

[218]  J. Collinge,et al.  Protein Conformation Significantly Influences Immune Responses to Prion Protein1 , 2005, The Journal of Immunology.

[219]  T. Yokoyama,et al.  Inhibition of prion propagation in scrapie-infected mouse neuroblastoma cell lines using mouse monoclonal antibodies against prion protein. , 2005, Biochemical and biophysical research communications.

[220]  B. Lucchini,et al.  Evaluation of Anti-Prionic Activity of Clioquinol in an in vivo Model (Mesocricetus auratus) , 2005, Veterinary Research Communications.

[221]  P. Tavan,et al.  Systematic Identification of Antiprion Drugs by High-Throughput Screening Based on Scanning for Intensely Fluorescent Targets , 2005, Journal of Virology.

[222]  A. Domb,et al.  Cationic polysaccharides as antiprion agents. , 2005, Journal of medicinal chemistry.

[223]  E. Sigurdsson,et al.  Mucosal vaccination delays or prevents prion infection via an oral route , 2005, Neuroscience.

[224]  S. Simon,et al.  Screening of 145 Anti-PrP Monoclonal Antibodies for Their Capacity to Inhibit PrPSc Replication in Infected Cells* , 2005, Journal of Biological Chemistry.

[225]  R. Kimberlin,et al.  The antiviral compound HPA-23 can prevent scrapie when administered at the time of infection , 2005, Archives of Virology.

[226]  M. Groschup,et al.  Charged bipolar suramin derivatives induce aggregation of the prion protein at the cell surface and inhibit PrPSc replication , 2005, Journal of Cell Science.

[227]  S. Biocca,et al.  KDEL-tagged anti-prion intrabodies impair PrP lysosomal degradation and inhibit scrapie infectivity. , 2005, Biochemical and biophysical research communications.

[228]  S. Supattapone,et al.  Protease-resistant Prion Protein Amplification Reconstituted with Partially Purified Substrates and Synthetic Polyanions* , 2005, Journal of Biological Chemistry.

[229]  N. Greig,et al.  Inhibition of P53-related apoptosis had no effect on PrPSc accumulation and prion disease incubation time , 2005, Neurobiology of Disease.

[230]  F. Heppner,et al.  Paracrine Inhibition of Prion Propagation by Anti-PrP Single-Chain Fv Miniantibodies , 2005, Journal of Virology.

[231]  John Collinge,et al.  Rational targeting for prion therapeutics , 2005, Nature Reviews Neuroscience.

[232]  B. Caughey,et al.  Comparison of protease-resistant prion protein inhibitors in cell cultures infected with two strains of mouse and sheep scrapie , 2005, Neuroscience Letters.

[233]  S. Biocca,et al.  Trapping Prion Protein in the Endoplasmic Reticulum Impairs PrPC Maturation and Prevents PrPSc Accumulation* , 2005, Journal of Biological Chemistry.

[234]  K. Kristensson,et al.  Inhibitors of the Mitogen-Activated Protein Kinase Kinase 1/2 Signaling Pathway Clear Prion-Infected Cells from PrPSc , 2005, The Journal of Neuroscience.

[235]  M. Clerici,et al.  Decrease in pathology and progression of scrapie after immunisation with synthetic prion protein peptides in hamsters. , 2005, Vaccine.

[236]  N. Mabbott,et al.  Follicular dendritic cell dedifferentiation reduces scrapie susceptibility following inoculation via the skin , 2005, Immunology.

[237]  B. Caughey,et al.  Potent Antiscrapie Activities of Degenerate Phosphorothioate Oligonucleotides , 2006, Antimicrobial Agents and Chemotherapy.

[238]  B. Caughey,et al.  Mefloquine, an Antimalaria Drug with Antiprion Activity In Vitro, Lacks Activity In Vivo , 2006, Journal of Virology.

[239]  V. Gillet,et al.  Library design, synthesis, and screening: pyridine dicarbonitriles as potential prion disease therapeutics. , 2006, Journal of medicinal chemistry.

[240]  S. Supattapone,et al.  Copper (II) ions potently inhibit purified PrPres amplification , 2006, Journal of neurochemistry.

[241]  G. J. Raymond,et al.  Inhibition of Protease-Resistant Prion Protein Formation in a Transformed Deer Cell Line Infected with Chronic Wasting Disease , 2006, Journal of Virology.

[242]  B. Caughey,et al.  A Porphyrin Increases Survival Time of Mice after Intracerebral Prion Infection , 2006, Antimicrobial Agents and Chemotherapy.

[243]  D. Berlin,et al.  Dextran Sulphate 500 Delays and Prevents Mouse Scrapie by Impairment of Agent Replication in Spleen , 2007 .